Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016

MM Al Malki, R Jones, Q Ma, D Lee, Y Reisner, JS Miller, P Lang, S Hongeng, P Hari, S Strober, J Yu, R Maziarz, D Mavilio, DC Roy, C Bonini, RE Champlin, EJ Fuchs, SO Ciurea

Research output: Contribution to journalArticle

Abstract

The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34 + cell selection, “megadoses” of purified CD34 + cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field. © 2018 The American Society for Blood and Marrow Transplantation
Original languageEnglish
Pages (from-to)895-908
Number of pages14
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Stem Cell Transplantation
Tissue Donors
Transplantation
T-Lymphocytes
Hematopoietic Stem Cell Transplantation
Hemoglobinopathies
Thalassemia
Sickle Cell Anemia
Organ Transplantation
Natural Killer Cells
Immunotherapy
Cyclophosphamide
Immunosuppression
Bone Marrow
Lymphocytes
Transplants
Recurrence
Survival
Mortality
Therapeutics

Cite this

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. / Al Malki, MM; Jones, R; Ma, Q; Lee, D; Reisner, Y; Miller, JS; Lang, P; Hongeng, S; Hari, P; Strober, S; Yu, J; Maziarz, R; Mavilio, D; Roy, DC; Bonini, C; Champlin, RE; Fuchs, EJ; Ciurea, SO.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 5, 2018, p. 895-908.

Research output: Contribution to journalArticle

Al Malki, MM, Jones, R, Ma, Q, Lee, D, Reisner, Y, Miller, JS, Lang, P, Hongeng, S, Hari, P, Strober, S, Yu, J, Maziarz, R, Mavilio, D, Roy, DC, Bonini, C, Champlin, RE, Fuchs, EJ & Ciurea, SO 2018, 'Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016', Biology of Blood and Marrow Transplantation, vol. 24, no. 5, pp. 895-908. https://doi.org/10.1016/j.bbmt.2018.01.008
Al Malki, MM ; Jones, R ; Ma, Q ; Lee, D ; Reisner, Y ; Miller, JS ; Lang, P ; Hongeng, S ; Hari, P ; Strober, S ; Yu, J ; Maziarz, R ; Mavilio, D ; Roy, DC ; Bonini, C ; Champlin, RE ; Fuchs, EJ ; Ciurea, SO. / Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 5. pp. 895-908.
@article{2e79e89448f84057970f0d41117cfc6c,
title = "Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016",
abstract = "The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34 + cell selection, “megadoses” of purified CD34 + cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field. {\circledC} 2018 The American Society for Blood and Marrow Transplantation",
author = "{Al Malki}, MM and R Jones and Q Ma and D Lee and Y Reisner and JS Miller and P Lang and S Hongeng and P Hari and S Strober and J Yu and R Maziarz and D Mavilio and DC Roy and C Bonini and RE Champlin and EJ Fuchs and SO Ciurea",
year = "2018",
doi = "10.1016/j.bbmt.2018.01.008",
language = "English",
volume = "24",
pages = "895--908",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016

AU - Al Malki, MM

AU - Jones, R

AU - Ma, Q

AU - Lee, D

AU - Reisner, Y

AU - Miller, JS

AU - Lang, P

AU - Hongeng, S

AU - Hari, P

AU - Strober, S

AU - Yu, J

AU - Maziarz, R

AU - Mavilio, D

AU - Roy, DC

AU - Bonini, C

AU - Champlin, RE

AU - Fuchs, EJ

AU - Ciurea, SO

PY - 2018

Y1 - 2018

N2 - The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34 + cell selection, “megadoses” of purified CD34 + cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field. © 2018 The American Society for Blood and Marrow Transplantation

AB - The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34 + cell selection, “megadoses” of purified CD34 + cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field. © 2018 The American Society for Blood and Marrow Transplantation

U2 - 10.1016/j.bbmt.2018.01.008

DO - 10.1016/j.bbmt.2018.01.008

M3 - Article

VL - 24

SP - 895

EP - 908

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -